Search
Powered By HealthLine
Special Offers
Health Tools
 Exercise and Fitness Guide
 Diet & Fitness Q&A
 Food Guide
 Diet Reviews
 Fitness and Family
Featured Conditions
 Diet & Exercise
 Food & Fitness
 High Blood Pressure
 Cholesterol
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Diabetes Drug Byetta May Aid Weight Loss in Obese Patients

Combined diet, exercise and injection had best results in study

By Jennifer Thomas
HealthDay Reporter


Related Encyclopedia
 border=
Abdominoplasty
Acidophilus
Addison's Disease
Ankle Sprains
More...

Related Healthscout Videos
 border=
Saving Money on Healthcare
Hungry Heart
Surgical Solution (LF)
Reversing Nerve Damage
More...

Related Animations
 border=
Allergy
Diabetes
More...

Related Drug Information
 border=
Actonel
Actos
Amaryl
Avandamet
More...

Related News Articles
 border=
Vitamin D Deficiency Linked to Cardiovascular Disease
Low Vitamin D Tied to Estrogen Decline
Developmental Delays Linked to Nicotine Gene?
Obese Teen Girls at Higher Risk for MS
More...

THURSDAY, June 11 (HealthDay News) -- Exenatide (Byetta), a drug normally used to treat diabetes, may also help non-diabetic obese people lose weight when combined with diet and exercise, new research has found.

Researchers divided 152 obese men and women (with a body-mass index of greater than 30 and an average weight of 241 pounds) into two groups. About 25 percent of the study participants had impaired glucose tolerance, which can be a precursor to diabetes.

Text Continues Below



One group received 10 micrograms of exenatide twice a day, while the other received a placebo. Both groups were put on a diet and exercise program for 24 weeks, according to the study authors.

After six months, those taking exenatide lost three times more weight than those taking the placebo, the researchers found. Participants taking exenatide lost an average of 11 pounds, while those in the placebo group lost 3.5 pounds on average.

Some 9.6 percent of exenatide-treated participants lost more than 10 percent of their body weight, according to the study authors.

"Drug therapy is considered important adjunctive treatment to diet and exercise in the successful management of obesity," Dr. Michael Trautmann, a researcher with Eli Lilly in Indianapolis, said in a news release from the Endocrine Society. "To date, however, there are few effective drugs that help obese people lose weight."

The study was to be presented Thursday at the annual meeting of the Endocrine Society in Washington, D.C.

Previous research has shown that exenatide, an injectable medication marketed by Amylin Pharmaceuticals and Eli Lilly and Company under the brand name Byetta, can help lower blood sugar and helps some diabetics lose weight. The current study was funded by the pharmaceutical companies.

The most common side effects of exenatide were mild or moderate nausea and diarrhea. No participants reported low blood sugar, the researchers note.

Exenatide may promote weight loss by causing people to eat less and increasing feelings of fullness, Trautmann said.

More information

The U.S. Centers for Disease Control and Prevention offers more on obesity.



-- Jennifer Thomas

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 6/11/2009

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake





SOURCE: Endocrine Society, news release, June 10, 2009


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy